A new initiative has just launched in the UK with the goal of increasing awareness and support for the more widespread use of photodynamic therapy (PDT). Compared to surgery and chemotherapy, PDT is a relatively simple, quick and effective treatment for certain types of cancer that we have covered previously on this blog.
Killingcancer.co.uk is a fundraising initiative aiming to create both a groundswell of interest and a pool of funds to support the development and access to PDT in the UK, to make it more readily available through the National Health Service (NHS). Through a mix of celebrity endorsements and patient stories they build an informative and compelling case for their cause.
Those of you that follow pharmaceutical development and Clinuvel in particular will know that we recently presented at Rodman and Renshaw’s 11th Annual Healthcare Conference in New York. It’s serendipitous that the following week found another conference taking place in the same city, although involving a rather different topic. The coincidence draws attention to a connection that is of increasing urgency and importance.
The launch of Clinuvel’s New Media channels mark the start of an exciting era in the company’s evolution. Although online information channels are not strictly part of classical pharmaceutical development, I believe that direct communication with drug developers will become the norm in our industry as part of greater accountability and transparency. Looking ahead, I wish to see Clinuvel in a leading position, not only by the progressive development of our ‘orphan drug’ 
